Applying Evolving Targeted Therapy in Acute Myeloid Leukemia

Access Activity

Overview / Abstract:

Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-selectin, and SMO. Dr. Jonas utilizes case studies to share his insights in the treatment of patients with AML.


Sep 30, 2024


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME



Credits / Hours




Is This Activity Certified for "Live" Credit?


Presenters / Authors / Faculty

Brian Jonas, MD, PhD
Professor of Medicine
University of California, Davis
Davis, California

Sponsors / Supporters / Grant Providers

This educational activity is supported by an educational grant from AbbVie.

Keywords / Search Terms

Annenberg Center for Health Sciences at Eisenhower Acute Myeloid Leukemia, AML Free CE CME Live CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map